You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

22 Items
Cancer Type: Gynecologic, Cervix     
Intent: Palliative
Drugs Used:
topotecan (Unfunded),
May 2019
Cancer Type: Sarcoma, Ewing's, Soft Tissue     
Intent: Palliative
Feb 2018
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL), Leukemia - Acute Myeloid (AML), Lymphoma - Non-Hodgkin's High Grade, Lymphoma - Non-Hodgkin's Intermediate Grade     
Intent: Curative, Palliative
May 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative
May 2019
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    daSAtinib - PH+ ALL, with specific criteria
May 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
Exceptional Access Program
    everolimus - In combination with exemestane, for the treatment of hormone-receptor positive, HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
ODB Limited Use
    exemestane - In combination with everolimus, for the treatment of hormone-receptor positive HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
Jun 2019
Cancer Type: Breast     
Intent: Adjuvant
Funding:
ODB Limited Use
    exemestane - Sequential treatment of postmenopausal women with estrogen receptor-positive early breast cancer who have received 2-3 years of initial adjuvant tamoxifen therapy
Jun 2019